Use of droloxifene for the treatment of protastic disease, endometriosis and obesity
OA: closed
AI-generated summary
This patent application describes a method for treating endometriosis, obesity, benign prostatic hypertrophy, and prostatic carcinoma in mammals by administering droloxifene or its pharmaceutically acceptable salts.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
PCT No. PCT/IB95/00404 Sec. 371 Date Jan. 6, 1997 Sec. 102(e) Date Jan. 6, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/02243 PCT Pub. Date Feb. 1, 1996This invention provides a method for treating a condition or disease selected from endometriosis, obesity, benign prostatic hypertrophy and prostatic carcinoma in mammals which comprises administering to said mammal an amount of droloxifene or a pharmaceutically acceptable salt thereof which is effective in treating said condition or disease.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-07-27T06:15:28.040536+00:00